Cerveau Technologies, Inc. and Enigma Biomedical Group, Inc., sign agreement with CAMH
BOSTON, Nov. 20, 2017 – Cerveau Technologies, Inc. and Enigma Biomedical Group, Inc., today announced an agreement with the Centre for Addiction and Mental Health (CAMH) in Toronto, Ontario to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.
As part of the agreement, Cerveau and Enigma will contract with CAMH to manufacture and supply the [18F]MK-6240 needed for the initiatives in the Greater Toronto Area.
"We are excited to have access to this next-generation tau imaging agent for diagnostic imaging of Alzheimer's disease and related dementias as well as for exploratory research on brain injuries," said Dr. Neil Vasdev, inaugural Director of the new Azrieli Centre for Neuro-Radiochemistry in CAMH's Campbell Family Mental Health Research Institute & Canada Research Chair in Radiochemistry and Nuclear Medicine at the University of Toronto. Dr. Vasdev has been working at the forefront of translating tau-PET radiopharmaceuticals including [18F]MK-6240 for human use.
"Cerveau and Enigma welcome this opportunity to work with CAMH researchers to understand the application of MK-6240 and how it may benefit patients with this devastating disease. The collaboration with CAMH will provide access to our pharmaceutical partners in support of various therapeutic trials as well as facilitate novel research at CAMH in the pursuit of evaluating potential preventive treatment options for Alzheimer's disease," said Rick Hiatt, President and CEO of Cerveau Technologies, Inc. and CEO of Enigma Biomedical Group, Inc.
"Continuing to build a research platform in Canada to support Alzheimer's research is a key priority at Enigma," said Lee Anne Gibbs, President of Enigma Biomedical Group, Inc., "the relationship with CAMH is a critical step to providing resources to the industry to combat Neurodegenerative diseases."
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in the area of addiction and mental health. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues.
Sean O'Malley, Media Relations, CAMH
416-535-8501 ext. 36663
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc., a Canadian Corporation, and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.
Cerveau Technologies, Inc.
Rick Hiatt, 6179062715